TY - JOUR
T1 - Drug Trials
T2 - Optimum Time of Publication
AU - Moore, Stephen
AU - Van Worest, Melvin H.
AU - Rosenbaum, David
PY - 1977/4/28
Y1 - 1977/4/28
N2 - To the Editor: As a clinician primarily interested in new developments in the therapy for myoclonus that might benefit my patients, I was misled by an initial reading of the Van Woert paper (N Engl J Med 296:70, 1977). The authors use the strength of their biologic and biochemical model to excuse their very inadequate clinical trial. They have reported an unblinded, uncontrolled drug trial on 18 patients, using the same neurologists to assess the improvement in myoclonus as were giving the carbidopa and L-5-hydroxytryptophan. They then point to the effects of these drugs on the urine and cerebrospinal-fluid. . .
AB - To the Editor: As a clinician primarily interested in new developments in the therapy for myoclonus that might benefit my patients, I was misled by an initial reading of the Van Woert paper (N Engl J Med 296:70, 1977). The authors use the strength of their biologic and biochemical model to excuse their very inadequate clinical trial. They have reported an unblinded, uncontrolled drug trial on 18 patients, using the same neurologists to assess the improvement in myoclonus as were giving the carbidopa and L-5-hydroxytryptophan. They then point to the effects of these drugs on the urine and cerebrospinal-fluid. . .
UR - http://www.scopus.com/inward/record.url?scp=0017784989&partnerID=8YFLogxK
U2 - 10.1056/NEJM197704282961723
DO - 10.1056/NEJM197704282961723
M3 - Letter
C2 - 321959
AN - SCOPUS:0017784989
SN - 0028-4793
VL - 296
SP - 1007
EP - 1008
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 17
ER -